In brief
The FDA and CDC have expanded their investigation into an outbreak of infant botulism linked to ByHeart's baby formula, affecting 51 infants across 19 states. The investigation indicates possible contamination in all ByHeart products produced since March 2022. The company recalled all its products on November 11, prompting increasing scrutiny over its manufacturing practices.
Federal health officials on Wednesday expanded an outbreak of infant botulism tied to recalled ByHeart baby formula to include all illnesses reported since the company began production in March 2022.
The U.S. Food and Drug Administration (FDA) stated that investigators are unable to rule out the possibility that contamination may have impacted all ByHeart formula products made to date.
The outbreak currently includes at least 51 infants across 19 states, while the Centers for Disease Control and Prevention (CDC) defines the new case category as “any infant with botulism who was exposed to ByHeart formula any time since its release.” The most recent case was noted on December 1.
Fortunately, there have been no reported fatalities as a result of this outbreak since it was first announced on November 8.
Previously, health officials had communicated that 39 suspected or confirmed cases of infant botulism were linked to ByHeart in 18 states, which rose to 51 with the new definition in relation to the initial report in August.
ByHeart, a New York-based manufacturer known for its organic infant formula, had been producing around 200,000 cans monthly, controlling about 1% of the U.S. infant formula market, before recalling all its products sold in the U.S. on November 11.
In response to the outbreak concerns, officials and parents have expressed alarm regarding the potential long-term contamination of ByHeart products.
Andi Galindo, whose daughter was hospitalized with infant botulism, shared her distress over the expanding outbreak findings. If there is proof of manufacturing issues affecting babies, they really need to be held accountable, she stated.
FDA inspectors were sent to ByHeart facilities in Iowa and Oregon for evaluations, although results have yet to be disclosed. Previous independent tests indicated contamination traces leading back to 2022, with a concerning history of issues in ByHeart's manufacturing practices noted in the past.
Infant botulism is rare, affecting fewer than 200 babies annually in the U.S., primarily affecting infants due to their immature gut microbiota. Symptoms may include constipation, poor feeding, and muscle weakness. Treatment consists of an IV medication known as BabyBIG, derived from adults' blood plasma, the sole treatment globally for this condition.
Several families have initiated lawsuits against ByHeart, citing allegations of negligence and defective products causing serious health risks to their infants.
